世界科学技术-中医药现代化2025，Vol.27Issue(4)：939-949,11.DOI:10.11842/wst.20240910007
从PI3K/AKT途径探讨益气健脾解毒复方对HBx介导肝癌干细胞干预作用的机制研究
Study on the Mechanism of the Intervention of Yiqi Jianpi Jiedu Compound on HBx-Mediated Liver Cancer Stem Cells from the Perspective of PI3K/AKT Pathway
摘要
Abstract
Objective To explore the mechanism of the intervention effect of Qizhu Xiaozheng Fang(QZXZF),a representative prescription of Yiqi Jianpi Jiedu(replenishing qi,strengthening spleen,and removing toxicity),in treating HBx-mediated liver cancer stem cells(LCSCs).Methods The Kaplan-Meier survival analysis was used to investigate the effects of Yiqi Jianpi Jiedu on the prognosis of patients with HBV-HCC.The network pharmacology method was utilized to predict the targets and pathways of QZXZF in treating HBx-related LCSCs(HBx-LCSCs).HBx-LCSCs cells were screened by stably transfecting HBx and serum-free culture.The therapeutic effect of QZXZF on HBx-LCSCs was tested in vitro,and its effect on stemness markers and PI3K/Akt pathway was verified by qRT-PCR and Western blot.Results Yiqi Jianpi Jiedu could improve the overall survival time of HBV-HCC patients.Combined with the results of network pharmacology,the mechanism of action of QZXZF against HBx-LCSCs was explored from the PI3K/Akt pathway.Compared with the blank vector group,HBx can promote the expression of stemness markers in HBx-LCSCs cells;compared with the HBx-LCSCs control group,QZXZF could significantly inhibit the proliferation and colony formation of HBx-LCSCs cells(in a concentration-dependent manner),and could reduce the expression of stemness markers(EpCAM,NANOG,SOX2,and OCT4),phosphorylated PI3K(p-PI3K)and phosphorylated AKT(p-AKT)proteins.Conclusion QZXZF may regulate HBx-mediated LCSCs through PI3K/AKT pathways,providing a reference for the mechanism of TCM intervention in LCSCs.关键词
益气健脾解毒/芪珠消癥方/叶下珠/肝癌干细胞/PI3K/AktKey words
Yiqi Jianpi Jiedu/Qizhu Xiaozheng Fang/Phyllanthus urinaria L./Liver cancer stem cells/PI3K/Akt分类
医药卫生引用本文复制引用
吴驻林,林森,罗维军,李思怡,张维晴,马澜月,魏春山,彭立生..从PI3K/AKT途径探讨益气健脾解毒复方对HBx介导肝癌干细胞干预作用的机制研究[J].世界科学技术-中医药现代化,2025,27(4):939-949,11.基金项目
国家自然科学基金委员会面上项目(82074384):从HBx-外泌体miRs-VEGFR2途径探讨叶下珠消癥汤抗肝癌作用机制,负责人:魏春山 （82074384）
深圳市龙华区医学会医学科研专项课题(2023LHMA02):叶酸修饰的负载槲皮素靶向纳米粒对HBx介导的HCC干性标志物影响的研究,负责人:吴驻林. （2023LHMA02）
